Free Trial

Syros Pharmaceuticals (SYRS) SEC Filings & 10K Form

Syros Pharmaceuticals logo
$0.01 +0.01 (+311.11%)
As of 10:46 AM Eastern

Recent Syros Pharmaceuticals SEC Filings

DateFilerForm TypeView
03/27/2025
5:17 PM
Samsara BioCapital, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13D/A
03/14/2025
3:43 PM
Fanucci Marsha (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
11:15 PM
Syros Pharmaceuticals (Filer)
Form EFFECT
03/11/2025
4:46 PM
Syros Pharmaceuticals (Subject)
WIRTH PETER (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2025
3:27 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:29 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:31 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:20 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:20 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:20 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:21 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
03/10/2025
3:21 PM
Syros Pharmaceuticals (Filer)
Form S-8 POS
02/14/2025
9:10 AM
Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
02/14/2025
7:41 AM
Deep Track Capital, LP (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
02/12/2025
8:41 AM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Syros Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
01/16/2025
3:49 PM
Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2025
3:01 PM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2024
4:11 PM
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/27/2024
3:02 PM
Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/13/2024
3:17 PM
Flagship VentureLabs IV, LLC (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
2:01 PM
Syros Pharmaceuticals (Subject)
Young Richard A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/06/2024
6:00 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2024
4:59 PM
Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2024
4:22 PM
Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
4:42 PM
Roth David (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
5:00 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
4:20 PM
Stephens Kristin (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
3:45 PM
Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
3:18 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
11:08 AM
Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2024
6:01 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
4:24 PM
Bain Capital Life Sciences Fund II, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
Form SC 13G/A
11/14/2024
4:28 PM
Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
Form SC 13G/A
11/13/2024
6:00 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
4:00 PM
Stephens Kristin (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
A new rule goes live in July — and the banks are quietly cashing in (Ad)

A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.

To help you get started, we're giving away a FREE Wealth Protection Guide that shows you exactly how
11/04/2024
4:01 PM
Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Roth David (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:01 PM
Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2024
5:49 AM
Syros Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/02/2024
4:00 PM
Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
4:00 PM
Syros Pharmaceuticals (Issuer)
Young Richard A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
4:00 PM
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
4:00 PM
Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
4:00 PM
Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:01 AM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
4:03 PM
Syros Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/02/2024
5:39 PM
Invus Global Management, LLC (Filed by)
Syros Pharmaceuticals (Subject)
Form SC 13G/A
07/31/2024
6:44 AM
Syros Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
07/31/2024
5:55 AM
Syros Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:SYRS) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners